Coding variants in tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) have been implicated in common variable immunodeficiency (CVID), but the functional effects of such mutations in relation to the development of the disease have not been entirely established. To examine the potential contribution of TNFRSF13B variants to CVID, we have applied an evolutionary approach by sequencing its coding region in 451 individuals belonging to 26 worldwide populations, in addition to controls, patients with CVID and selective IgA deficiency (IgAD) from Italy. The low level of geographical structure for the observed genetic diversity and the several neutrality tests performed confirm the absence of recent population-specific selective pressures, suggesting that TNFRSF13B may be involved also in innate immune functions, rather than in adaptive immunity only. A slight excess of rare derived alleles was found in patients with CVID, and thus some of these variants may contribute to the disease, implying that CVID probably fits the rare variants rather than the common disease/common variant paradigm. This also confirms the previous suggestion that TNFRSF13B defects alone do not cause CVID and that such an extremely heterogeneous immunodeficiency might be more likely related to additional, still unknown environmental and genetic factors.
Introduction
The tumor necrosis factor receptor superfamily member 13B gene (TNFRSF13B, OMIM 604 907) codes for the tumor necrosis factor (TNF) receptor-like transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Such protein is mainly expressed on the surface of several B-cell subpopulations, in particular on marginal zone B cells and on CD27
þ memory B cells. 1, 2 It binds to the TNF ligands Bcell activating factor and a proliferation-inducing ligand, having a function in the regulation of isotype switching, survival and differentiation of B lymphocytes, in a very complex functional network that is crucial for humoral responses. 3 In the recent years, clinical genetics studies on individuals affected by common variable immunodeficiency (CVID) and selective IgA deficiency (IgAD) have led to the identification of a certain number of TNFRSF13B coding variants in a limited subset of patients. CVID (OMIM 240 500) is characterized by reduced serum levels of at least two different immunoglobulin isotypes and represents the most frequent symptomatic antibody deficiency, with a prevalence of 1:30 000, in Europeans and in North Americans of European ancestry. IgAD is even more common, with an estimated prevalence of 1:700 in the same populations; however, it is often asymptomatic and most cases remain undiagnosed. 4 After the initial claim of a strict association of TNFRSF13B mutations with both diseases, 5 the analysis of further control samples has shown the existence of some of these variants also in healthy individuals and, in familial cases, TNFRSF13B mutations do not always perfectly segregate with the pathological phenotype. 6 This has led to a reevaluation of the actual function of TNFRSF13B variants in IgAD and CVID onset, in which only the C104R and A181E mutations showed a clear correlation with the development of CVID. 7, 8 However, even the A181E association was not statistically significant in all studies. Moreover, other heterozygous TNFRSF13B changes have shown incomplete penetrance, suggesting that they actually increase the risk to develop CVID, but are not sufficient alone to cause it. 9, 10 Although genetic association studies have delivered a number of solidly significant associations, they are notoriously prone to produce inconsistent results. The choice of surveyed markers, possible inadequate sample sizes or remarkable heterogeneity of cases, as well as many other factors, may appreciably influence the reliability of their results. 11 Given the complex and still ambiguous scenario depicted by case-control studies with respect to the involvement of TNFRSF13B in these diseases, we have employed the more comprehensive perspective of an evolutionary approach, as already carried out for other genes with medical implications. [12] [13] [14] The rationale behind this approach is that if natural selection has acted on a given locus, a specific imprint in its genetic diversity could be observed and this may turn out to be very useful for an exhaustive understanding of the gene function. Two cases leave particular footprints in genetic diversity: if selective pressures are geographically localized, as it is often the case with pathogen-related genes, and if balancing selection, in which genetic diversity per se is being favored by selection, is operating. Genes involved in adaptive immunity, such as TNFRSF13B, are likely to fall in the former category, 15 as they may interact with the local pathogen landscape, resulting in increased interpopulation differentiation. To test such hypotheses, we have sequenced the TNFRSF13B coding region in 451 healthy individuals belonging to 26 worldwide populations from sub-Saharan Africa, North Africa, the Middle East, central Asia and South America, in addition to control subjects, patients with CVID and IgAD and Val di Scalve individuals from Italy, whereas all previous clinical studies were based on samples of European ancestry only. This has allowed us to obtain for the first time a global picture of nucleotide diversity and haplotype structure at the TNFRSF13B locus and to suggest an evolutionary history for such a gene, also by exploring potential, very recent, evolutionary events through the analysis of the well-defined historical isolate of Val di Scalve. All that in the attempt to elucidate which diversity falls into the standard degree of intraspecific TNFRSF13B variation and which instead may be related to CVID and IgAD phenotypes.
Results

Polymorphic variation
Polymorphic variation at the TNFRSF13B coding region was investigated by sequencing a total of 2254 base pairs (bp), encompassing its five exons and their immediately intronic flanking regions, in 902 chromosomes from healthy individuals belonging to 26 worldwide populations, 154 and 76 chromosomes from Italian patients with CVID and IgAD, respectively.
Sequence variations (35:33 biallelic single-nucleotide polymorphisms (SNPs), 1 insertion, 1 deletion) were identified (Table 1; Figure 1 ) and their genotype frequencies resulted in accordance with the HardyWeinberg equilibrium in all groups. Coding variants 204insA, C104R, A181E and C193X have been previously observed in several case-control studies. [5] [6] [7] Among them, 204insA, A181E and C193X resulted private patient mutations, with A181E exclusive of cases with CVID and 204insA and C193X that are also found in cases with IgAD. On the contrary, substitution C104R was present both in Italians with CVID and IgAD and in healthy Italians. Changes 204insA and C104R, together with I87N, C104Y and 358_359delA, affect the two cysteinerich domains (CRDs) that constitute TACI extracellular region. In particular, ligand-binding CRD-2 substitutions I87N and C104R have been recently predicted to be deleterious because they may lead to energy changes at a TACI stability center and to increase in protein disorders and steric clashes. 10 On the contrary, variants A181E and C193X affect TACI transmembrane and intracellular domains, the former responsible of transmitting ligand-induced conformational changes and the latter structured to recruit signaling proteins such as TNFRassociated factors and the calcium modulator and cyclophilin ligand. In this case, substitution A181E has been predicted to be deleterious by altering a TACI stability center. 10 Genetic diversity Summary statistics of genetic diversity for the TNFRSF13B coding region are reported in Table 2 . Nucleotide diversity (p), calculated as the average heterozygosity per site, was 0.00110 for the total sample and did not change significantly after excluding patients with CVID and IgAD from the analysis. Compared to literature available values, such statistic results to be nearly twice the mean value estimated for 292 autosomal genes (p ¼ 0.00058), 16 higher than the mean value calculated from the 320 genes resequenced by the Seattle SNPs project (p ¼ 0.00085) (http://pga.gs.washington. edu/) and also higher than the value obtained as an average for 8 genes from the Innate Immunity Program in Genomics Application database (p ¼ 0.00094) (http:// innateimmunity.net/), recently surveyed for signatures of selection. 17 The sub-Saharan African sample showed one of the lowest values of nucleotide diversity (p ¼ 0.00063), in contrast with the trend observed for several other genes, [18] [19] [20] but see Mateu et al. 21 for a counterexample, and for Seattle SNPs resequenced genes, for which African Americans showed greater nucleotide diversity than European Americans in 82.6% of the cases.
Haplotype diversity (H), defined as the probability of two haplotypes randomly chosen in the sample to be different, also resulted lower in the sub-Saharan African sample (H ¼ 0.802) respect to the North African and Middle Eastern samples (H ¼ 0.849 and 0.822, respectively), pointing out again at an unusual scarceness of variability in the former.
Divergence between humans and chimpanzees Fixed nucleotide differences (15) were observed between healthy humans and the chimpanzee, one of which, a C to G transversion at nucleotide position 23 342, leads to the amino-acid substitution P146A. A total divergence (Dxy) of 0.75% was calculated, together with its apportionment in noncoding (Ki), synonymous (Ks) and nonsynonymous (Ka) divergence. A Ki of 1% was estimated on the basis of the 1375 noncoding bp analyzed and resulted lower than the 1.27% computed as the average value for 12 997 autosomal genes; 22 only B5% of these genes have lower noncoding divergences. We also found small values of Ks (0.87%) and Ka (0.18%) with respect to genome-wide average values (Ks ¼ 1.42%, Ka ¼ 0.34%), but they fall, respectively, in the 37 and 47 percentiles of the genome-wide distribution. Finally, as a conventional statistic for the measure of global evolutionary constraint on genes, we estimated the Ka/Ks ratio, obtaining a value of 0.202, which is similar enough to 0.23, the mean value reported by The Chimpanzee Sequencing and Analysis Consortium. 22 In summary, both within the human species and when compared to our closest ancestor, TNFRSF13B seems to be evolving at a slightly slower, though not unusual, rate for which no particular explanation seems necessary.
Haplotype structure and linkage disequilibrium pattern An ancestral haplotype (not found in the analyzed samples) was inferred by using the chimpanzee TNFRSF13B reference sequence to recover the putative ancestral allele at each polymorphic site. The haplotype reconstruction (Table 3 ) led to the identification of a greater number of haplotypes (64) with respect to that of haplotype-constituting variants (35) , emphasizing the considerable level of recombination occurred within the TNFRSF13B gene. 16, 23 The five most frequent inferred haplotypes accounted for 68% of sampled chromosomes ( Figure 2 ). Among them, haplotypes h3, h6 and h9 were found in all groups except in the Val di Scalve, reaching a cumulative frequency of 46%. In particular, h3 was the most represented haplotype nearly in all populations, with a frequency always X25%, except for the central Asian sample (7%). Other two common haplotypes in the total sample were h1 and h2. The former was anyway rare in sub-Saharan Africans (1.8%) and even completely absent in central Asians and South Americans; whereas the latter, the most closely related to the ancestral haplotype inferred from the chimpanzee sequence (with a single divergent site at position 90), was not observed in the Italian and Val di Scalve samples. In the five haplotypes mentioned above, the only represented polymorphisms are intronic substitutions 23 376A4C, 32 153T4G, 32 232T4C, synonymous changes T27T and S277S and replacement substitution P251L, which are the more ancient and globally widespread TNFRSF13B variants.
The remaining 32% of analyzed chromosomes is accounted for by 18 haplotypes, with frequencies in the total sample that range from 0.27 to 3.18% and merge into a cumulative frequency of 20%; by 40 rare haplotypes found only once or twice in the total sample, 
with a cumulative frequency of 4%, and finally by haplotype h20, whose global frequency of 8% is mainly due to the very high frequency observed in a single group (48% in Val di Scalve), in contrast to only 2% in the Middle Eastern sample. In North Africans, rare haplotypes account for 18% of sampled chromosomes, a higher percentage also in comparison to patients with CVID and IgAD (11 and 9%, respectively), followed by sub-Saharan African and Middle Eastern samples (8%), Italians, central Asians and South Americans (7%) and finally by the Val di Scalve sample (3%).
Haplotypes in cases and controls with CVID Italian control and samples with CVID and IgAD showed a very similar haplotype frequency distribution concerning the five most frequent worldwide haplotypes h1, h2, h3, h6, h9 and the Italian and Middle Eastern distinctive haplotypes h8, h22, h25, which carried synonymous substitution P97P and replacement change V220A, in addition to nearly the same polymorphisms of the first set. The eight haplotypes mentioned above accounted for 89% of control chromosomes and for 91 and 84% of IgAD and CVID chromosomes, respectively. Cases with CVID showed another nonrare haplotype (h27) carrying the supposed pathogenic replacement change C104R, 24 with a higher but not significantly different frequency with respect to the control sample (3.25 vs 1.04%; Fisher's exact test, P ¼ 0.25). Rare haplotypes accounted for 7% of analyzed chromosomes in the control sample, whereas their frequency rose to 9% in cases with IgAD and 11% in cases with CVID. Only three rare haplotypes turned out to be exclusive of controls and of cases with IgAD (on a total of 11 and 6 rare haplotypes, respectively), whereas private ones were 11 in cases with CVID (on a total of 14). Among them, haplotypes h53, h47 and h49 carried the supposed pathogenic replacement change A181E.
Examining the median joining network constructed for the cases and controls pooled sample (Figure 3) , we noticed that haplotypes h50 and h51 (carrying substitu- TNFRSF13B evolution and CVID M Sazzini et al tion C104Y and deletion 358_359delA, respectively) were one-step neighbors of the most represented haplotype h3, in addition to h53, h47 and h49. On the contrary, haplotypes h45 and h55 (carrying substitution C193X and insertion 204insA, respectively) derived from the second most frequent haplotype (h1), as well as the IgAD cases private haplotype h40, which carried both mutations at the same time. The remaining four private IgAD cases haplotypes carried instead intronic variants 32 153T4G, 32 232T4C, 31 518G4T, 23 376A4C and synonymous change P97P. Finally, haplotype h41 (with the supposed pathogenic substitution C104R) resulted exclusive of cases with IgAD.
Population structure
Genetic distances among 24 worldwide populations were measured using F st as an estimate of their allele frequency differentiation. A graphical representation of such distances was obtained from the computed genetic distance matrix by means of a nonmetric multidimensional scaling (NM-MDS; Figure 4 ). This revealed that a clear pattern of geographical structure for TNFRSF13B genetic diversity was hardly recognizable, because North African, Middle Eastern, Italian samples with CVID and IgAD and healthy samples were in fact gathered into a single cluster and central Asian populations only seemed to form a separate group, probably as a consequence of their lowest sequence diversity, due to smaller sample sizes.
Statistical support for the absence of a sharp geographical structure for TNFRSF13B genetic diversity was also provided by analysis of molecular variance (AMO-VA) results, which showed very low levels of differentiation among geographically based groups of populations (sub-Saharan Africa, North Africa, the Middle East, Europe, central Asia and South America) (F ct ¼ 0.0559, Po0.001), in comparison to the average F ct value of 0.10 estimated for 109 DNA loci, 25 28 Finally, the same F st index was also used to measure genetic distances between Italian diseases and healthy groups of individuals. Comparing sample with IgAD and control sample we found an F st value of À0.00629 (P ¼ 0.823), whereas a thin difference was observed between the sample with CVID and the control one, but with a borderline statistical significance (F st ¼ 0.01046, P ¼ 0.043).
Neutrality tests
We sought for genetic footprints of selection at the TNFRSF13B locus by computing several neutrality tests based on the comparison of human intraspecific genetic diversity and human/chimpanzee interspecific divergence (McDonald-Kreitman and Hudson-KreitmanAguadé (HKA) tests) and on the frequency spectrum of mutations (Tajima's D, Fu and Li's D, F and Fay and Wu's H; Table 2 ), because it is proved that they are less sensitive to misspecifying recombination in comparison to those based on haplotypes distribution or mismatch distribution. 29, 30 In this way we could properly test departures from the null hypothesis of neutral evolution within the pattern of sequence variation observed at this gene.
The McDonald-Kreitman test showed that the ratio of TNFRSF13B synonymous to nonsynonymous variation is equal within and between Homo sapiens and Pan troglodytes (P ¼ 0.788). Nonsignificant differences were also observed by comparing the TNFRSF13B ratio of 
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M Sazzini et al polymorphism to fixed human/chimpanzee differences with those observed for two autosomal regions (intron 44 of the DMD gene 31 and the HBB 32 gene) for which no evidence of selection was found (HKA test, P ¼ 0.358 and P ¼ 0.532, respectively).
After correction for multiple testing, as well as after coalescent simulations performed to evaluate their statistical significance, Tajima's D estimate for the total sample and Fu and Li's D and F statistics for both samples with CVID and total samples only resulted significantly different from zero (Table 2 ). In both cases large negative values were obtained, reflecting an excess of singletons and low-frequency variants that, as regards the sample with CVID, can be interpreted as an evidence of the actual involvement of some TNFRSF13B sequence variations in the disease phenotype. Significant values observed for the total sample may be instead explained by the higher statistical power of tests on such a greater group and by the effect of demographic expansion of anatomically modern humans on the H. sapiens genome, as seen in most of our genes. 16 Finally, even if not significantly different from zero the large positive Tajima's D value for the Val di Scalve sample (Table 2 ) suggests a condition close to a scarceness of segregating sites and to an excess of intermediate frequency alleles that may be interpreted as a consequence of a founder effect, followed by strong genetic drift.
Discussion
The evolution of TNFRSF13B The function of the TNFRSF13B protein product, the TNF receptor-like TACI, in the regulation of isotype switching, survival and differentiation of B lymphocytes is nowadays only partially understood, 3 as well as the degree of association of such gene variants with the heterogeneous spectrum of CVID. 7, 8 Up to the present, clinical genetics studies, which investigate on TNFRSF13B involvement in CVID, autoimmune disorders and some other diseases, are principally based on European and North American of European ancestry cases and controls, [5] [6] [7] [8] 33 with very few exceptions. 34, 35 In this work, we thus describe for the first time the nucleotide diversity and the haplotype structure at the TNFRSF13B coding region in a worldwide panel of human populations. For this purpose, we have sequenced its five exons and their immediately intronic flanking regions in individuals from sub-Saharan Africa, Figure 3 Median joining network of TNFRSF13B haplotypes in Italian patients and controls with cases with common variable immunodeficiency (CVID) and selective IgA deficiency (IgAD). Nodes are proportional to haplotype frequencies, whereas branch lengths are proportional to the number of variants occurred in the sequences, except for the branch tracing back to the chimpanzee, which encompasses 15 divergent nucleotide positions between humans and chimpanzee.
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North Africa, the Middle East, central Asia and South America, in addition to Val di Scalve, controls, subjects with CVID and IgAD from Italy, to obtain a reliable and global picture of the genetic variability that characterizes this locus. As a matter of fact, analyzing population samples with different ancestry has allowed us to suggest an evolutionary history for the TNFRSF13B gene, an approach that could turn out to be truly significant for shedding light on its actual function in immune functions and, consequently, in the development of a so complex and multifaceted disease such as CVID.
TNFRSF13B genetic diversity was characterized by an unusual scarceness of variability for the examined subSaharan African populations. In contrast with the trend observed for several other genes, [18] [19] [20] this sample displayed one of the lowest values of nucleotide diversity, as well as a lower value of haplotype diversity with respect to North African and Middle Eastern samples. Usually a lower level of genetic diversity is found in non-African populations and it is universally accounted as a consequence of the strong bottleneck experienced by the groups of modern humans that migrated out of Africa, starting from 100 000 to 50 000 years ago. 36 We suggest that the peculiar higher TNFRSF13B variability observed in North African, Middle Eastern and European samples may be principally due to the presence of D41G, M48I, C104R, C104Y, R198R, S209P, V220A coding variants and 10 intronic substitutions, which have arisen in the ancestors of such populations during the early dispersal of anatomically modern humans out of sub-Saharan Africa. An excessive number of TNFRSF13B changes should be not the optimum for survival in ancestral sub-Saharan Africans, given the huge amount of bacterial pathogens encountered during childhood. On the contrary, the presence of endemic tuberculosis (TB) since in ancestral northern African populations might have allowed the spread of TNFRSF13B defects. As a matter of fact, it has been proved that a strong reduction of well-functioning B cells causes an exacerbated pulmonary pathology during TB acute phase, but subsequently leads to a reduced inflammatory progression during its chronic phase. 37 That being so, a weak wastefulness in B cells function may still support granulomatous response and effective immunity, which are essential for contrasting the acute infection, and, at the same time, may provide a significant decreased perpetuation of local inflammatory responses during TB chronic phase, leading to less immunopathology over time. This may be one of the reasons why new TNFRSF13B changes started to be anciently maintained in first H. sapiens groups that left sub-Saharan Africa and have subsequently spread in Eurasian populations. In this way TNFRSF13B changes might be still tolerated in early childhood in modern human populations, especially in those in which health care and hygiene conditions have been strongly improved, subsequently leading to an increased susceptibility to CVID. On the contrary, low values of variability for central Asian, South American and Val di Scalve samples may rather reflect the stronger action that genetic drift exerts on such smaller and more isolated populations. This is particularly true for the Val di Scalve sample, for which the presence of a single predominant haplotype and the results of neutrality tests suggest the occurrence of a founder effect followed by strong genetic Looking back to the evolutionary history of such a young and cosmopolitan species as H. sapiens, it is coherent to believe that our pathogens, which live in the extremely diversified environments colonized by modern humans, may have represented one of the major selective pressures on our genome. Thereby, genes whose function is strictly related to the immune system are supposed to be more likely subjected to the action of natural selection respect to other typology of genes, as recently confirmed by Sabeti et al. 38 In particular, genes involved in adaptive immunity, such as TNFRSF13B, are likely to be subjected to recent geographically localized selective pressures, as they may interact with local pathogen landscapes, resulting in increased interpopulations genetic differentiation. We therefore sought for genetic footprints of selection at the TNFRSF13B gene by means of several neutrality tests based on the frequency spectrum of mutations (Tajima's D, Fu and Li's D, F and Fay and Wu's H) and on the comparison of human intraspecific genetic diversity and human/chimpanzee interspecific divergence (McDonald-Kreitman and HKA tests). However, no evidence for recent populationspecific selective pressures was found. This finding was also confirmed by the nearly homogeneous genetic background of worldwide populations emphasized by AMOVA results and by very similar F ct values for each sequence variation across the gene, leading to the acceptance of a neutral model of evolution for the analyzed genomic region. Nevertheless, such an absence of sharp TNFRSF13B interpopulation genetic differentiation, in spite of its proved function in humoral responses, is not so unlikely if we take into account the recent remarks about relationships between innate and adaptive components of the immune system 39, 40 and the hypothesis of a not negligible involvement of its protein product TACI in innate immune functions. Comparing the haplotypes in Italian diseases and control groups, we observed a very similar frequency distribution to that found in worldwide populations and, in particular, to that of the Middle Eastern sample. Considering the frequency of both cosmopolitan and rare haplotypes, an extremely subtle difference is noticed between samples with IgAD and control samples, whereas a greater difference is found when subjects with CVID are examined. Statistical support for these case-control differences is given by AMOVA results, which showed a barely significant F st value for CVIDcontrols comparison only.
Neutrality tests also resulted very useful for further chracterizing and distinguishing Italian samples with CVID and IgAD and control samples. Even if the pattern of sequence variation observed at the TNFRSF13B locus did not show significant departures from the null hypothesis of neutral evolution, neutrality statistics turned out to be informative about the peculiar history of each analyzed group. A larger negative, although nonsignificant, Tajima's D estimate and significant Fu and Li's F and D values for the sample with CVID with respect to the sample with IgAD reflect a more substantial excess of singletons and low-frequency variants in the former, whereas the latter presents values very close to those observed in the control sample. A difference between subjects with CVID and IgAD is again emphasized, suggesting an actual involvement of TNFRSF13B variants in CVID, but not in IgAD.
In conclusion, our evolutionary analysis has demonstrated that the examined cohort of patients with CVID carries an excess of rare derived alleles, with respect to that of healthy individuals belonging to the same population, some of which may contribute to the disease phenotype. Such an excess may suggest that CVID does not fit the common disease/common variant paradigm, 41 for which alleles contributing risk for a common disease are supposed to be frequent in the general population, but rather fits the rare variants hypothesis. 42 This model proposes that a significant proportion of the inherited susceptibility to common diseases is due to the effects of a series of low-frequency variants, each conferring a moderate increase in the relative risk, present on different genes. According to this view, our results confirm the previous hypothesis that TNFRSF13B defects alone do not cause CVID and that such an extremely heterogeneous immunodeficiency might be more likely related to still unknown environmental and genetic factors rather than to the nature of TNFRSF13B variants only. 6 Kirgiz from Sary-Tash, 7 Uyghurs); South America (9 Quechuas from Tayacaja, 10 Aymara from Lake Titicaca, 10 Quechuas from Lake Titicaca, 8 Yanesha, 4 Arequipa) and Europe (96 Italian blood donors, with an age over 55 years, and 96 Italians from Val di Scalve). The sample of Italian blood donors was the sole used as a control group to perform case-control comparisons, whereas the remaining population samples were exclusively used to perform evolutionary analyses. In particular, the Val di Scalve sample was collected as an example of isolated population. Val di Scalve is indeed a North Italian valley colonized in the last 5000 years only and surrounded by peaks belonging to the Orobie Prealps that have maintained its communities isolated from the neighboring valleys for a long time. A written informed consent was collected from each subject and the study was designed according to the ethical principles for medical TNFRSF13B evolution and CVID M Sazzini et al research involving human subjects stated by the World Medical Association Declaration of Helsinki.
Materials and methods
Population samples
Sequence analysis DNA was extracted from peripheral blood samples using a modified salting-out protocol. The coding region of the TNFRSF13B gene (GenBank accession no. NG_007281) was amplified in five segments corresponding to the exons of the gene and their immediately intronic flanking regions, encompassing a total of 2254 bp for each individual. Amplification reactions were performed in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) as previously described, 5 except for exon 5 that required a new couple of primers (F 5 0 -CCCCGGCACAGGTTCTGGTC-3 0 and R 5 0 -TCCTCCTTTCCCTCCCTGAC-3 0 ) and a different annealing temperature (64 1C). PCR products were purified with a vacuum pump system on a Montage PCR kit (Millipore, Bedford, MA, USA) then used for sequencing reaction with ABI Prism BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). Sequencing was performed on an ABI 3730 DNA Analyzer (Applied Biosystems) after fragment purification on a Montage SEQ96 Sequencing Reaction Cleanup Kit (Millipore). The software Sequencher 4.6 (http://www.genecodes.com) was used to align the sequences to the TNFRSF13B reference sequence (NG_007281.1 GenBank) and to detect polymorphic sites. For each of them, calculations of allele and genotype frequencies, as well as the HardyWeinberg equilibrium test and the relative correction for multiple testing, were performed using the Arlequin 3.01 package. 43 Haplotype inference and linkage disequilibrium analysis Haplotypes were statistically inferred from unphased genotype data by means of the Bayesian algorithm implemented in the software PHASE version 2.1 44, 45 using the default settings, with the exception of the number of iterations (1000 rather than 100), as recommended in Graffelman et al. 46 All 35 polymorphic sites detected were used in haplotype reconstruction, but samples with 450% missing genotypes were dropped from the analysis. The chimpanzee TNFRSF13B reference sequence (NC_006484.2 GenBank; Pan_troglodytes 2.1 assembly) was used to define the putative ancestral allele at each SNP, except for the intronic substitution C4T at position 90, where the chimpanzee sequence carries a G. In this case, we considered as ancestral the most frequent allele in the samples analyzed.
The extent of LD at the TNFRSF13B locus was measured by computing the r 2 statistic, as well as the Fisher's exact test used to assess its statistical significance, with the DnaSp package 47 Phylogenetic analysis Evolutionary relationships among the inferred haplotypes were visualized by means of the median joining network algorithm 49 implemented in the Network 4.5.0.0 software (http://www.fluxus-engigeering.com). One network was constructed for each population, for the total pooled sample and for a cases and controls pooled sample. An estimate of TNFRSF13B coding region mutation rate per site per year (m) of 6.22 Â 10 À10 was obtained by dividing the total nucleotide divergence between human samples (excluding patients with CVID and IgAD) and the chimpanzee (Dxy ¼ 0.00746) by twice the divergence time between the species (6 million years).
Analysis of population structure
The apportionment of genetic variance among geographically based groups of populations and between Italian cases and controls was investigated with a locus by locus AMOVA. 50 Excluding Arequipa and Egyptians because of their very small sample sizes, AMOVA and F st genetic distances among 24 worldwide populations, as well as between patients and controls with CVID and IgAD, were computed using the Arlequin 3.01 package. 43 A Slatkin's linearized genetic distance matrix 51 was used for a graphical representation by means of an NM-MDS. 52 Because Val di Scalve stood out as a clear outlier in the first NM-MDS plotting, relegating the other populations in a cloud that was very hard to disentangle, this sample was subsequently excluded from NM-MDS and AMOVA computations.
Neutrality tests
Departures from the null hypothesis of neutral evolution at the TNFRSF13B gene were tested with the DnaSp package 47 version 4.50.2, by computing different typologies of neutrality statistics. Tests based on the comparison of human intraspecific genetic diversity and human/chimpanzee interspecific divergence (McDonald-Kreitman 53 and HKA 54 tests) were performed on the total sample, but excluding individuals with CVID and IgAD. The McDonald-Kreitman test was used to verify if the ratio of polymorphism to fixed human/ chimpanzee differences is comparable between synonymous and nonsynonymous TNFRSF13B changes, whereas the HKA test was applied to compare the same ratio with that observed for genomic regions of comparable size and for which no evidence of selection was found. On the contrary, population samples were clustered into five geographically based groups (subSaharan Africa, North Africa, the Middle East, central Asia and South America), whereas Italian controls, Italians from the isolate of Val di Scalve, patients with CVID and IgAD were maintained as four independent samples to perform the following neutrality tests based on the frequency spectrum of mutations: Tajima's D, 55 Fu and Li's D*, F* and D, F (with a chimpanzee sequence as an out-group) 56 and Fay and Wu's H (with a chimpanzee sequence as an out-group). 57 Using the same software, we also tested the statistical significance of such statistics by running 10 
